Genmab shares jump as ovarian cancer drug shows durable responses in trial

What happened: Genmab shares rose more than 4% after its experimental ovarian cancer drug Rina-S showed durable responses in patients with platinum-resistant ovarian cancer in a mid-stage trial. Key numbers: Confirmed objective response rate 45.9% among 109 patients, including five complete responses. Why it matters: The data include the first progression-free survival results reported for the program, and Genmab's Chief Medical Officer said they reinforce the potential of Rina-S as the company advances its Phase 3 program.

Genmab shares rose more than 4% after its experimental ovarian cancer drug Rina-S showed durable responses in patients with platinum-resistant ovarian cancer in a mid-stage trial.

The data include the first progression-free survival results reported for the program, and Genmab's Chief Medical Officer said they reinforce the potential of Rina-S as the company advances its Phase 3 program.